GLP-1 receptor agonists — the class that includes semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — have transformed how doctors think about type 2 diabetes and obesity. A new head-to-head analysis published in The BMJ on August 10, 2026 now adds another layer: in adults living with both type 2 diabetes and established heart disease, tirzepatide was linked to a roughly one-third lower risk of a major cardiovascular event compared with a standard diabetes drug. The finding sharpens a question many patients and clinicians are asking — are these medications also becoming heart drugs?
What the new BMJ study found
Researchers led by Nils Krüger, MD, MPH, analyzed electronic health records for nearly 53,000 adults with type 2 diabetes and pre-existing cardiovascular disease. Patients newly started on tirzepatide were matched with patients newly started on sitagliptin (Januvia), a dipeptidyl peptidase-4 inhibitor widely used as a cardiovascular-neutral comparator.
After one year of follow-up, the rate of major adverse cardiovascular events — a composite of heart attack, stroke, and cardiovascular death — was 2.9 percent in the tirzepatide group versus 4.4 percent in the sitagliptin group. That translated to a 33 percent lower relative risk. In practical terms, the authors calculated that treating about 70 similar patients with tirzepatide instead of sitagliptin for one year would prevent one major cardiovascular event.
Because the study used real-world records rather than a randomized design, it cannot prove tirzepatide caused the difference. But the large sample size, careful matching, and use of a cardiovascular-neutral comparator make the signal difficult to dismiss.
How it fits with earlier trials
The BMJ analysis lands on top of a growing pile of randomized evidence for the broader GLP-1 class. The landmark SELECT trial, published in The New England Journal of Medicine in 2023, followed more than 17,000 adults with overweight or obesity and established cardiovascular disease (but not diabetes) and found that semaglutide 2.4 mg reduced the composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke by 20 percent over a mean follow-up of about three years.
Earlier cardiovascular outcome trials — LEADER for liraglutide and REWIND for dulaglutide, both published in NEJM — showed similar reductions in cardiovascular events in people with type 2 diabetes. The American Heart Association’s 2024 scientific statement now recognizes GLP-1 receptor agonists as an evidence-backed option for cardiovascular risk reduction in high-risk patients.
Full outcomes data for tirzepatide specifically will come from the SURPASS-CVOT trial, a randomized comparison of tirzepatide and dulaglutide in more than 13,000 people with type 2 diabetes and cardiovascular disease. Results are expected to help confirm whether the observational signals hold up under randomized conditions.
Why might these drugs protect the heart?
Cardiologists and endocrinologists point to several overlapping mechanisms rather than a single one.
Weight loss and metabolic effects
Tirzepatide produced average weight loss above 20 percent in the SURMOUNT-1 obesity trial published in NEJM in 2022. Excess body weight strains the heart, drives high blood pressure, and worsens sleep apnea and lipid profiles. Even modest sustained weight loss is associated with reductions in cardiovascular events in observational data.
Better blood sugar control
Sustained hyperglycemia damages the endothelium — the delicate lining of blood vessels — and accelerates atherosclerosis. GLP-1 drugs improve glycemic control by boosting insulin secretion in response to meals and slowing gastric emptying.
Blood pressure and lipids
Trials have consistently shown small but real reductions in systolic blood pressure (typically 3 to 5 mmHg) and modest improvements in triglycerides. Over years, small changes at the population level translate into meaningful event reductions.
Anti-inflammatory and vascular effects
Research published in journals such as Circulation suggests GLP-1 receptor agonists lower high-sensitivity C-reactive protein, a marker of vascular inflammation, and may improve endothelial function through pathways that are not entirely dependent on weight loss or glucose control.
Who benefits most?
The strongest evidence base is in three overlapping groups: adults with type 2 diabetes and established cardiovascular disease, adults with obesity and established cardiovascular disease, and adults with type 2 diabetes at high cardiovascular risk. Guidelines from the American Diabetes Association and the American College of Cardiology now recommend a GLP-1 receptor agonist with proven cardiovascular benefit as a preferred agent in many of these patients, alongside SGLT2 inhibitors.
The BMJ study population was specifically people with both diabetes and heart disease — the group most likely to see absolute benefit. Whether the same magnitude of benefit extends to people without established heart disease is a separate question that ongoing trials are designed to answer.
What the study does not tell us
Observational data can identify associations but cannot fully rule out that patients who received tirzepatide differed in some unmeasured way from those who received sitagliptin — access to care, adherence, or lifestyle factors, for example. It also does not tell us how long benefits persist after stopping the drug, how they compare directly with semaglutide, or how they play out over five or ten years.
Side effects also matter. Gastrointestinal symptoms — nausea, vomiting, constipation — are common early on. Rare but serious risks such as pancreatitis, gallbladder disease, and a possible link to a specific eye condition called NAION are still being characterized. As with any prescription decision, the calculation involves individual risk and benefit.
The bottom line
Evidence continues to accumulate that GLP-1 receptor agonists — long thought of primarily as diabetes and weight-loss drugs — carry meaningful cardiovascular benefits for people at high risk. The new BMJ analysis adds tirzepatide to the cardiovascular story in a way that mirrors what earlier trials showed for semaglutide, liraglutide, and dulaglutide.
For anyone weighing whether one of these medications fits their situation, the decision belongs in a conversation with a healthcare provider who can weigh personal history, cardiovascular risk, other medications, and cost against the strengthening evidence of benefit.
Disclosure: This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.